| Name | Title | Contact Details |
|---|
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.
4G Clinicals suite of innovative RTSM and clinical supply optimization software provides the right-sized support for any phase or trial complexity. At 4G Clinical, all studies are supported by a team of RTSM experts to advise trial teams on the best path forward. Our operations team distinguishes itself through their extensive industry expertise and deep understanding of trial designs and mid-study adjustments. 4G Clinical is committed to helping sponsors and CROs follow the science, wherever it may lead, as quickly and as safely as we can. While we will not discover the next novel compound in the lab, we are doing our part by leveraging our extensive experience and technological innovations to bring speed and agility to clinical trials. As a critical partner throughout clinical development, we can help you seamlessly transition and scale your trials through both protocol and supply complexities to help bring crucial medicines to those who need them, faster. To learn more about how we are tackling the bottlenecks in clinical trials through our innovative solutions, Prancer RTSM® and 4C Supply®, visit us at www.4gclinical.com.
Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.
Hygiena is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.